Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8161 |
Name | oncocytic carcinoma of the thyroid |
Definition | A thyroid gland follicular carcinoma that is characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma follicular thyroid carcinoma oncocytic carcinoma of the thyroid |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET fusion | Selpercatinib | oncocytic carcinoma of the thyroid | sensitive | detail... |
RET fusion | Pralsetinib | oncocytic carcinoma of the thyroid | sensitive | detail... |
BRAF V600E | Vemurafenib | oncocytic carcinoma of the thyroid | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | oncocytic carcinoma of the thyroid | sensitive | detail... |
MLH1 negative | Pembrolizumab | oncocytic carcinoma of the thyroid | sensitive | detail... |
MSH6 negative | Pembrolizumab | oncocytic carcinoma of the thyroid | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02973997 | Phase II | Lenvatinib + Pembrolizumab | Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03002623 | Phase II | CUDC-907 | CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer | Terminated | USA | 0 |
NCT03215095 | Phase I | Durvalumab | RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers | Active, not recruiting | USA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT03914300 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04321954 | Phase II | Lenvatinib | Lenvatinib in Locally Advanced Invasive Thyroid Cancer | Recruiting | USA | 0 |
NCT05453799 | Phase II | XmAb20717 | Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer | Unknown status | USA | 0 |
NCT05852223 | Phase II | Pembrolizumab | Pembrolizumab in High-risk Thyroid Cancer (NePenThe) | Not yet recruiting | ITA | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT06440850 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Recruiting | USA | 0 |